CoChat

Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy

Yaghoubi, Sajad, Karimi, Mohammad Hossein, Lotfinia, Majid, Gharibi, Tohid, Mahi‐Birjand, Motahare, Kavi, Esmaeil, Hosseini, Fahimeh, Sineh Sepehr, Koushan, Khatami, Mehrdad, Bagheri, Nader, Abdollahpour‐Alitappeh, Meghdad · 2020 · Journal of Cellular Physiology
Cited by 152

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Cytotoxic small‐molecule drugs have a major influence on the fate of antibody–drug conjugates (ADCs). An ideal cytotoxic agent should be highly potent, remain stable while linked to ADCs, kill the targeted tumor cell upon internalization and release from the ADCs, and maintain its activity in multidrug‐resistant tumor cells. Lessons learned from successful and failed experiences in ADC development resulted in remarkable progress in the discovery and development of novel highly potent small molecules. A better understanding of such small‐molecule drugs is important for development of effective ADCs. The present review discusses requirements making a payload appropriate for antitumor ADCs and focuses on the main characteristics of commonly‐used cytotoxic payloads that showed acceptable results in clinical trials. In addition, the present study represents emerging trends and recent advances of payloads used in ADCs currently under clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcp.28967

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 152

Metadata

Authors
Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi‐Birjand, M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., & Abdollahpour‐Alitappeh, M.
Venue
Journal of Cellular Physiology
Publisher
Wiley
Published
2019-06-18
Volume
235
Issue
1
Pages
31-64
ISSN
  • 0021-9541 (ISSN-L)
  • 1097-4652
OpenAlex
W2950613960
Cited by
152
References
10
FWCI
11.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. https://app.cochat.ai/papers/10.1002/jcp.28967
The paper
Yaghoubi, S., Karimi, M. H., Lotfinia, M., Gharibi, T., Mahi‐Birjand, M., Kavi, E., Hosseini, F., Sineh Sepehr, K., Khatami, M., Bagheri, N., & Abdollahpour‐Alitappeh, M. (2020). Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.28967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.